Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Charlson Comorbidity Index

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Charlson Comorbidity Index. Displaying page 1 of 1.
    EudraCT Number: 2017-002914-30 Sponsor Protocol Number: LCZ696-17 Start Date*: 2017-11-06
    Sponsor Name:FIMABIS
    Full Title: LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magne...
    Medical condition: Chronic heart failure NYHA class II-IV with reduced ejection fraction (EF =< 40%) and elevated NT-proBNP ≥ 600 pg/mL, but 400 pg/mL if hospitalized for heart failure within 12 months
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002072-26 Sponsor Protocol Number: P150939 Start Date*: 2016-08-25
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Multicenter randomized placebo controlled trial assessing the efficacy of oral adjuvant magnesium supplementation in the treatment of alcohol withdrawal syndrome.
    Medical condition: Patients experiencing an alcohol withdrawal syndrome.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10037175 - Psychiatric disorders 10053164 Alcohol withdrawal syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001647-20 Sponsor Protocol Number: WeCabE Start Date*: 2014-11-18
    Sponsor Name:GIOGer (Gruppo Italiano di Oncologia Geriatrica)
    Full Title: Weekly cabazitaxel in elderly MCRPC (Metastatic Castration Resistant Prostate Cancer) patients progressing after docetaxel treatment: a phase II study
    Medical condition: Castration resistant metastatic prostate cancer progressing after docetaxel based treatment
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002448-21 Sponsor Protocol Number: ACTIVATEII Start Date*: 2020-05-26
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036897 Prophylactic vaccination LLT
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001639-38 Sponsor Protocol Number: GEMCAD-16-03 Start Date*: 2017-07-19
    Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
    Full Title: A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good ...
    Medical condition: First-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-012413-21 Sponsor Protocol Number: I08011 Start Date*: 2009-08-04
    Sponsor Name:CHU Limoges
    Full Title: Etude de phase II évaluant un traitement par cisplatine et vinorelbine orale administrés de façon hebdomadaire et radiothérapie concomitante chez le sujet âgé indépendant atteint de cancer broncho-...
    Medical condition: No small cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029519 Non-small cell lung cancer stage III LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002845-39 Sponsor Protocol Number: Infmed1 Start Date*: 2019-10-02
    Sponsor Name:Aalborg University Hospital
    Full Title: Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL)
    Medical condition: Brain abscess
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10006105 Brain abscess PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003382-10 Sponsor Protocol Number: PazoQol Start Date*: 2018-02-28
    Sponsor Name:GWT-TUD GmbH
    Full Title: Quality of life in patients with non-adipocyte soft tissue sarcoma under palliative chemotherapy or pazopanib – a randomized, controlled trial- PazoQoL
    Medical condition: Soft tissue sarcoma (STS)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003963-20 Sponsor Protocol Number: AIO-YMO/TRK-0416 Start Date*: 2017-10-24
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC
    Medical condition: metastatic non-small cell lung cancer (NSCLC)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003007-38 Sponsor Protocol Number: 56021927PCR3003 Start Date*: 2016-01-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
    Medical condition: High- or very-high risk, localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BE (Trial now transitioned) NL (Completed) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000399-28 Sponsor Protocol Number: AIO-NZK-0115/ass. Start Date*: 2016-12-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitin...
    Medical condition: advanced or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000542-20 Sponsor Protocol Number: UC-0103/1802 Start Date*: 2021-01-07
    Sponsor Name:UNICANCER
    Full Title: Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program
    Medical condition: Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006674-22 Sponsor Protocol Number: 56021927PCR2046 Start Date*: 2022-12-12
    Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s.
    Full Title: AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Prospective institutional phase II study of efficacy and safety of androgen deprivation with apalutamide in high-risk ...
    Medical condition: Localized or a locally advanced high-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004486-37 Sponsor Protocol Number: 59812 Start Date*: 2017-09-19
    Sponsor Name:University Medical Centre Utrecht
    Full Title: FOsfomycin Randomised controlled trial for E.coli Complicated urinary tract infections as Alternative Stepdown Treatment
    Medical condition: Acute febrile urinary tract infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017512 10046574 Urinary tract infection NOS LLT
    20.0 100000017512 10046576 Urinary tract infection, site not specified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002602-24 Sponsor Protocol Number: ISASOCUT Start Date*: 2023-03-31
    Sponsor Name:CHU DE POITIERS
    Full Title: Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001271-16 Sponsor Protocol Number: AGO-OVAR28 Start Date*: 2022-08-01
    Sponsor Name:AGO Research GmbH
    Full Title: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
    Medical condition: Patients with newly diagnosed, histologically confirmed, primary advanced invasive high grade epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, FIGO stage III/IV (except FIGO ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 17:50:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA